An observational study in Infectious Disease, sponsored by Maranatha Christian University. Completed at 1 site in Indonesia. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by Maranatha Christian University · Observational
This is the first Case Studies article highlight factors determine the effectiveness of Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images before and after the patients received the therapy. This Case Studies gives a huge contribution as CPT still on going as multicentre study and apply massively as emergency approved treatment in Indonesia.
Eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320. This study has three goals included to detect the improvement of patient clinical and laboratory conditions, safety of CPT, and conversion from positive to negative results after CPT administration. Convalescent plasma applied within two weeks (13 days) from onset of illness and within a week (6.5 days) from the first day of hospital admission for all patients. Improvements in clinical symptoms, laboratory parameters, thorax photo, negative conversion of PCR, and decreased oxygen supplementation occurred within a week after CPT. Patients with two doses of CP tended to have faster recovery than those with one dose of CP. No severe adverse effects were observed in any patient. This is the first case series in Indonesia showing CPT is safe and well tolerated, and early CPT before the patient is intubated could potentially prevent disease progression, increase the recovery rate, and shorten the inpatient days.
626 studies on the registry are indexed under Communicable Diseases; 128 are open to participants now.
This study's enrollment of 8 is below the median of 200 across 228 observational studies indexed under Communicable Diseases.
Browse Communicable Diseases studies →Maranatha Christian University is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All eight patients originated from one region of Tangerang with positive PCR swab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.
Biological: Convalescent Plasma Therapy
Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.
Biological: Convalescent Plasma Therapy
In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
Patients with two doses of CP tended to have faster recovery than those with one dose of CP.
The median time from onset of illness to CPT was 13 days (within two weeks), and from the first day of hospital admission to CPT was 6.5 days (within a week). There were improvements in clinical symptoms, laboratory parameters, thorax photo, negative conversion of PCR, and decreased oxygen supplementation within a week after CPT. No severe adverse effects were observed in any patient.
Time frame: 1 April 2020 - 31 December 2020
Patients with two doses of CP tended to have faster PCR negative conversion time than those with one dose of CP
All four patients given two doses of CP became negative in PCR swab but only two of four patients given one dose of CPT showed negative PCR swab result
Time frame: 1 April 2020 - 31 December 2020
Plan to share: No
Ran from Apr 2020 to primary completion in Dec 2020, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maranatha Christian University